Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Average Rating of “Buy” from Analysts

Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) have received a consensus recommendation of “Buy” from the seven analysts that are presently covering the company, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $30.20.

ATXS has been the subject of several recent research reports. Citigroup reaffirmed an “outperform” rating on shares of Astria Therapeutics in a report on Wednesday, August 13th. JMP Securities increased their price target on Astria Therapeutics from $25.00 to $26.00 and gave the stock a “market outperform” rating in a report on Wednesday, August 13th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $49.00 price objective on shares of Astria Therapeutics in a research report on Wednesday. Finally, HC Wainwright increased their price objective on Astria Therapeutics from $16.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Cubist Systematic Strategies LLC raised its position in Astria Therapeutics by 503.7% in the first quarter. Cubist Systematic Strategies LLC now owns 92,239 shares of the biotechnology company’s stock worth $493,000 after acquiring an additional 76,961 shares in the last quarter. Deutsche Bank AG raised its position in Astria Therapeutics by 54.3% in the fourth quarter. Deutsche Bank AG now owns 39,744 shares of the biotechnology company’s stock worth $355,000 after acquiring an additional 13,986 shares in the last quarter. Hsbc Holdings PLC increased its position in shares of Astria Therapeutics by 70.3% in the first quarter. Hsbc Holdings PLC now owns 32,808 shares of the biotechnology company’s stock valued at $174,000 after buying an additional 13,545 shares in the last quarter. GAMMA Investing LLC increased its position in shares of Astria Therapeutics by 1,127.4% in the first quarter. GAMMA Investing LLC now owns 8,678 shares of the biotechnology company’s stock valued at $46,000 after buying an additional 7,971 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Astria Therapeutics by 13.9% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 63,452 shares of the biotechnology company’s stock valued at $567,000 after buying an additional 7,756 shares in the last quarter. Hedge funds and other institutional investors own 98.98% of the company’s stock.

Astria Therapeutics Price Performance

Shares of NASDAQ ATXS opened at $7.05 on Friday. The stock has a fifty day moving average price of $6.77 and a 200 day moving average price of $5.76. Astria Therapeutics has a 1-year low of $3.56 and a 1-year high of $12.92. The company has a market cap of $397.90 million, a PE ratio of -3.51 and a beta of 0.42.

Astria Therapeutics (NASDAQ:ATXS) last issued its quarterly earnings results on Tuesday, August 12th. The biotechnology company reported ($0.57) earnings per share for the quarter, topping the consensus estimate of ($0.61) by $0.04. Analysts anticipate that Astria Therapeutics will post -1.65 earnings per share for the current fiscal year.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.